(Q41548829)

3 October 2017

Expression of complement receptor 2 (CR2) on HTLV-1-infected lymphocytes and transformed cell lines (English)

1 reference

Human T-lymphotropic virus 1

3 October 2017

0 references

author name string

McNearney TA

1

1 reference

3 October 2017

Ebenbichler CF

2

1 reference

3 October 2017

Tötsch M

3

1 reference

3 October 2017

Dierich MP

4

1 reference

3 October 2017

language of work or name

English

0 references

publication date

1 June 1993

1 reference

European Journal of Immunology

3 October 2017

1 reference

3 October 2017

23

1 reference

3 October 2017

6

1 reference

3 October 2017

1266-1270

1 reference

Expression of CR2 (C3d receptor) on the cell membranes of adult T cell leukemia.

3 October 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

The regulators of complement activation (RCA) gene cluster

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Replication of Epstein–Barr virus in human epithelial cells infected in vitro

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Infection of human thymocytes by Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Functional and antigenic properties of complement receptor type 2, CR2.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Growth control of activated, synchronized murine B cells by the C3d fragment of human complement

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Cell cycle control of activated, synchronized murine B lymphocytes—roles of macrophages and complement C3

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Enhancement of Epstein-Barr virus/C3d receptor (EBV/C3dR or CR2) and nuclear p120 ribonucleoprotein phosphorylation by specific EBV/C3dR ligands in subcellular fractions of the human B lymphoma cell line, Raji

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Transformation of human umbilical cord blood T cells by human T-cell leukemia/lymphoma virus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Isolation and transmission of human retrovirus (human t-cell leukemia virus).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Antigenic features of human follicle stimulating hormone delineated by monoclonal antibodies and construction of an immunoradiomometric assay

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Human T-cell leukemia virus (HTLV-I) transcripts in fresh and cultured cells of patients with adult T-cell leukemia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830230611

7 January 2021

Identifiers

DOI

10.1002/EJI.1830230611

1 reference

3 October 2017

1 reference